9 completed, 3 withdrawn, 2 active not recruiting, 2 unknown. 18 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 9, Withdrawn 3, Active not recruiting 2, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis Rituximab, Ocrelizumab, Fexofenadine - Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 600 | 2021-04-28 | 2026-08-17 |
| Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease Rituximab, Ocrelizumab - Relapsing Remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Haukeland University Hospital | 214 | 2020-11-02 | 2025-06-27 |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
| A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 ALKS 8700, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 506 | 2017-03-15 | 2020-07-14 |
| A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-01-01 | 2021-11-09 | |
| Vitamin D Supplementation in Multiple Sclerosis Vitamin D3 - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Johns Hopkins University | 172 | 2012-03-01 | 2022-09-28 |
| Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) NU100, Placebo, rhIFN beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 3 | Unknown | Nuron Biotech Inc. | 500 | 2011-10-01 | 2013-09-23 |
| Advanced MRI Measures of Repair in Alemtuzumab Treated Patients MabCampath-1h - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | University of British Columbia | 27 | 2011-03-01 | 2018-10-16 |
| Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis BIIB017 - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Johns Hopkins University | 2010-08-01 | 2014-09-15 | |
| A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo Glatiramer acetate (GA), Placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1404 | 2010-06-22 | 2021-12-09 |
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 84 | 2010-03-01 | 2014-09-03 |
| Safety of New Formulation of Glatiramer Acetate Glatiramer Acetate, Experimental Glatiramer Acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 147 | 2009-07-01 | 2017-03-14 |
| Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis Simvastatin, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Anna Tsakiri | 2008-03-01 | 2014-02-20 | |
| A Study for Patients With Relapsing Remitting Multiple Sclerosis dirucotide, placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 218 | 2006-11-01 | 2010-09-09 |
| Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1155 | 2006-08-01 | 2011-10-10 |
| A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis Simvastatin - Relapsing Remitting Multiple Sclerosis | Phase 3 | Unknown | Alabama Neurology Associates, PC | 30 | 2005-10-01 | 2005-12-07 |
| Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo simvastatin, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Tehran University of Medical Sciences | 80 | 2005-04-01 | 2010-07-30 |
| Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx Interferon beta 1-a, glatiramer acetate, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Fred Lublin | 1008 | 2005-01-01 | 2014-04-03 |
Multiple Sclerosis, Relapsing-Remitting (18) · Multiple Sclerosis (5) · Autoimmune Diseases (2) · Multiple Sclerosis, Chronic Progressive (2) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Recurrence (1)
Autoimmune Diseases of the Nervous System (17) · Demyelinating Autoimmune Diseases, CNS (17) · Demyelinating Diseases (17) · Immune System Diseases (17) · Nervous System Diseases (17) · Autoimmune Diseases (16) · Multiple Sclerosis (13) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Leukoencephalopathies (1)
Glatiramer Acetate (5) · Interferon beta-1a (3) · Rituximab (3) · Simvastatin (3) · ocrelizumab (3) · Alemtuzumab (2) · Natalizumab (2) · Acetaminophen (1) · Cholecalciferol (1) · Cladribine (1) · Dimethyl Fumarate (1) · MBP-8298 (1) · Methylprednisolone (1) · fexofenadine (1) · laquinimod (1)
Teva Branded Pharmaceutical Products R&D, Inc. (4) · Biogen (2) · Johns Hopkins University (2) · Alabama Neurology Associates, PC (1) · Anna Tsakiri (1) · Copenhagen University Hospital, Rigshospitalet (1) · Eli Lilly and Company (1) · Fred Lublin (1) · Haukeland University Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nuron Biotech Inc. (1) · Tehran University of Medical Sciences (1) · University of British Columbia (1)
United States (7) · Poland (5) · Bulgaria (3) · Canada (3) · Hungary (3) · Italy (3) · Russia (3) · Ukraine (3) · Croatia (2) · Czechia (2) · Denmark (2) · Georgia (2) · Germany (2) · Serbia (2) · Spain (2)
Anthony Traboulsee, MD (1) · Chen Duksin, MD (1) · Ellen M Mowry, MD, MCR (1) · Emily S. Riser, MD (1) · Fred Lublin, MD (1) · George E. Georges, MD (1) · Giancarlo Comi, Prof (1) · Jeffrey A. Cohen, MD (1) · Jeppe Romme Christensen, MD, PhD (1) · Jette L Frederiksen, DMSC (1) · Kjell-Morten Myhr, MD (1) · Mansooreh Togha, MD (1)
PMID 20488825, PMID 23424159, PMID 24686106, PMID 25311447, PMID 27503905, PMID 31289819, PMID 31953790, PMID 32539719, PMID 32554770, PMID 33796143, PMID 34376508, PMID 34433679, PMID 34695274, PMID 34759712, PMID 34927308, PMID 36382118, PMID 37119208, PMID 37125397, PMID 37830451, PMID 38878121, PMID 42384870, PMID 42663866
2009 (1), 2017 (1), U01NS045719 (1), UM1AI109565 (1)